Table 1 |
|||||
|
Secreted cytokine array. Secreted proinflammatory cytokines down-regulated by HA, anti-MIF antibody and MIF anti-sense. Integrated density values (IDV, average intensity times total area) were determined for each individual cytokine dot. Individual cytokine dot intensities were normalized to HRP-positive controls on each membrane. Mean control data for each cytokine spot are expressed as protein ratios (cytokine specific band integrated density value divided by HRP-positive control integrated density value). Treatment data are expressed as +, greater than 2 fold increase in secretion compared with control cytokine spot; -, greater than 2 fold decrease in secretion compared with control cytokine spot; (-), decreased beyond detection. |
|||||
|
Cytokine Family |
|||||
|
|
|||||
|
Control (Mean Protein Ratio) |
HA |
α-MIF |
AS |
||
|
|
|||||
|
Chemokine CC |
|||||
|
CCL2 |
1.27 ± 0.04 |
- |
(-) |
||
|
CCL4 |
0.30 ± 0.02 |
- |
(-) |
(-) |
|
|
CCL5 |
0.18 ± 0.01 |
- |
(-) |
(-) |
|
|
CCL11 |
0.11 ± 0.01 |
(-) |
(-) |
(-) |
|
|
CCL15 |
0.41 ± 0.04 |
(-) |
(-) |
- |
|
|
CCL17 |
0.12 ± 0.01 |
- |
(-) |
(-) |
|
|
CCL18 |
1.97 ± 0.07 |
- |
(-) |
- |
|
|
CCL20 |
0.69 ± 0.04 |
(-) |
- |
||
|
CCL22 |
0.19 ± 0.02 |
- |
(-) |
- |
|
|
CCL23 |
0.12 ± 0.01 |
(-) |
(-) |
(-) |
|
|
CCL24 |
0.14 ± 0.01 |
- |
(-) |
- |
|
|
CCL26 |
0.20 ± 0.01 |
(-) |
(-) |
(-) |
|
|
CXC Chemokine |
|||||
|
CXCL1 |
0.16 ± 0.02 |
- |
- |
(-) |
|
|
CXCL2 |
0.15 ± 0.02 |
- |
- |
(-) |
|
|
CXCL5 |
0.19 ± 0.02 |
- |
(-) |
(-) |
|
|
CXCL6 |
0.26 ± 0.03 |
- |
- |
- |
|
|
CXCL7 |
1.56 ± 0.03 |
- |
(-) |
- |
|
|
CXCL8 |
0.32 ± 0.02 |
- |
- |
||
|
CXCL9 |
0.16 ± 0.01 |
- |
(-) |
- |
|
|
CXCl10 |
1.60 ± 0.17 |
- |
- |
- |
|
|
CXCL12 |
0.15 ± 0.01 |
- |
(-) |
- |
|
|
CXCL13 |
0.34 ± 0.02 |
- |
(-) |
- |
|
|
CXC3C Chemokine |
|||||
|
CX3CL1 |
0.19 ± 0.01 |
- |
(-) |
||
|
Cytokines |
|||||
|
Leptin |
0.19 ± 0.02 |
- |
(-) |
(-) |
|
|
LIF |
3.20 ± 0.04 |
- |
|||
|
MIF |
0.64 ± 0.04 |
(-) |
(-) |
(-) |
|
|
OSM |
0.20 ± 0.02 |
- |
(-) |
(-) |
|
|
Interferon |
|||||
|
INF-γ |
0.17 ± 0.02 |
- |
(-) |
(-) |
|
|
Neurotropins |
|||||
|
BDNF |
1.10 ± 0.05 |
- |
- |
||
|
GDNF |
1.30 ± 0.07 |
- |
|||
|
NT-3 |
2.00 ± 0.11 |
- |
(-) |
||
|
NT-4 |
0.79 ± 0.04 |
- |
(-) |
- |
|
|
Enzymes |
TIMP-1 |
2.54 ± 0.11 |
- |
||
|
TIMP-2 |
5.29 ± 0.29 |
- |
+ |
||
|
Growth Factors |
|||||
|
Ang-1 |
0.20 ± 0.02 |
(-) |
(-) |
||
|
EGF |
0.17 ± 0.03 |
- |
(-) |
- |
|
|
FGF-4 |
0.24 ± 0.03 |
- |
(-) |
(-) |
|
|
FGF-6 |
0.18 ± 0.01 |
- |
(-) |
- |
|
|
FGF-9 |
0.81 ± 0.05 |
- |
|||
|
HGF |
0.12 ± 0.02 |
- |
(-) |
(-) |
|
|
MCSF |
0.15 ± 0.02 |
- |
(-) |
(-) |
|
|
PGIF |
0.64 ± 0.05 |
- |
(-) |
- |
|
|
Inhibin |
0.17 ± 0.02 |
- |
(-) |
(-) |
|
|
TGF β-2 |
3.20 ± 0.03 |
- |
|||
|
TGF β-3 |
0.77 ± 0.02 |
- |
(-) |
(-) |
|
|
Hormone-like protein |
|||||
|
IGF-1 |
0.14 ± 0.01 |
(-) |
(-) |
(-) |
|
|
IGFBP-1 |
2.40 ± 0.10 |
- |
|||
|
IGFBP-2 |
1.40 ± 0.06 |
- |
- |
||
|
IGFBP-3 |
2.50 ± 0.12 |
- |
(-) |
||
|
IGFBP-4 |
0.11 ± 0.01 |
- |
(-) |
- |
|
|
TP-3 |
0.13 ± 0.01 |
- |
(-) |
(-) |
|
|
Interleukins |
|||||
|
IL-1α |
0.20 ± 0.01 |
- |
(-) |
(-) |
|
|
IL-1β |
0.14 ± 0.02 |
- |
(-) |
(-) |
|
|
IL-2 |
0.14 ± 0.04 |
- |
(-) |
(-) |
|
|
IL-12 |
0.16 ± 0.01 |
- |
(-) |
(-) |
|
|
IL-15 |
0.10 ± 0.09 |
- |
(-) |
(-) |
|
|
IL-16 |
0.27 ± 0.04 |
- |
(-) |
- |
|
|
PDGF Superfamily |
|||||
|
PDGF-B |
0.17 ± 0.02 |
- |
(-) |
(-) |
|
|
P1GF |
0.59 ± 0.04 |
- |
(-) |
- |
|
|
VEGF |
3.20 ± 0.48 |
- |
+ |
- |
|
|
TNF Superfamily |
|||||
|
TNFSF14 |
0.19 ± 0.01 |
- |
- |
(-) |
|
|
TNFSF2 |
0.13 ± 0.02 |
(-) |
(-) |
- |
|
|
TNFRSF11B |
4.40 ± 0.04 |
- |
|||
|
CD Ligands |
|||||
|
Fit-3 |
0.07 ± 0.01 |
- |
- |
(-) |
|
|
|
|||||
|
Meyer-Siegler et al. BMC Cancer 2004 4:34 doi:10.1186/1471-2407-4-34 |
|||||
